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Abstract
Genetic risk factors for intracranial aneurysm (IA) are not yet fully understood. Genomewide
association studies have been successful at identifying common variants; however, the role
of rare variation in IA susceptibility has not been fully explored. In this study, we report the
use of whole exome sequencing (WES) in seven densely-affected families (45 individuals)
recruited as part of the Familial Intracranial Aneurysm study. WES variants were prioritized
by functional prediction, frequency, predicted pathogenicity, and segregation within fami-
lies. Using these criteria, 68 variants in 68 genes were prioritized across the seven families.
Of the genes that were expressed in IA tissue, one gene (TMEM132B) was differentially ex-
pressed in aneurysmal samples (n=44) as compared to control samples (n=16) (false dis-
covery rate adjusted p-value=0.023). We demonstrate that sequencing of densely affected
families permits exploration of the role of rare variants in a relatively common disease such
as IA, although there are important study design considerations for applying sequencing to
complex disorders. In this study, we explore methods of WES variant prioritization, including
the incorporation of unaffected individuals, multipoint linkage analysis, biological pathway
information, and transcriptome profiling. Further studies are needed to validate and charac-
terize the set of variants and genes identified in this study.
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Introduction
Subarachnoid hemorrhage (SAH) is the most devastating subtype of stroke. Fatality from SAH
between 21 days to one month of the hemorrhage ranges from 25–35% in high-income coun-
tries to almost 50% in low- to middle-income countries [1]. Up to 80–90% of SAH cases are
caused by rupture of intracranial aneurysms (IA), which are present in approximately 3% of
the population [2]. Smoking and hypertension are important risk factors, increasing the risk of
IA rupture by 3.1 and 2.6 times respectively [3]. The risk of an IA and for IA rupture is also in-
creased among individuals having a first-degree relative with a history of an IA [2, 4, 5]. The lo-
cation and number of IAs in a given individual also appears to be influenced by a family
history [6]. Thus, several lines of evidence suggest that IA is due to both genetic and environ-
mental risk factors. Unfortunately, until more is understood about these risk factors, the severe
morbidity and mortality associated with this disease will continue to be a large public
health burden.
Several approaches have been employed to identify genes contributing to IA. Initial studies
utilized pedigrees having multiple affected members. Analyses in these initial studies detected
linkage to several chromosomal regions (1p34.3–36.13 [7, 8], 4q32.2 [9], 6p23 [10],7q11 [7],
7q36.3 [9], 8q12.1 [9], 11q24–25 [10–12], 12q21.33 [9], and 14q23–31 [12]); however, the caus-
ative gene was not identified in any of these regions. More recently, genomewide association
studies (GWAS) have focused on the role of common variants that might individually have a
small effect on disease risk. Analyses have consistently detected association to single nucleotide
polymorphisms in CDKN2BAS, also known as ANRIL, on chromosome 9p21.3 [13–15], as well
as SOX17 on chromosome 8q12.1 [13–15]. Association has also been reported to EDNRA on
chromosome 4q31 [16], CNNM2 on chromosome 10q24 [14], KL/STARD13 on chromosome
13q13 [14], and RBBP8 on chromosome 18q11 [14]. Together, these genes only explain a frac-
tion of the population attributable risk for IA.
Advances in technology, especially in the development of high-throughput sequencing, now
make it possible to efficiently search for rare variants having a large effect on disease risk.
These rare variants may point to novel genes and pathways that are critical to improve the mo-
lecular understanding of IA and methods of predicting those at greatest risk. In the present
work, whole exome sequencing (WES) was applied to a unique set of families densely affected
with IA to investigate the role of rare genetic variation in disease susceptibility and to demon-
strate important study design considerations for WES studies in complex disease.
Materials and Methods
Families Selected for Whole Exome Sequencing
Individuals were recruited as part of the Familial Intracranial Aneurysm (FIA) Study [17].
Study approval was granted by institutional review boards at Indiana University, University of
Cincinnati, Mayo Clinic, University of Medicine and Dentistry of New Jersey, Cleveland Clinic,
Columbia University, University of Texas Houston, Indianapolis Neurosurgical Group, Good-
man Campbell Brain and Spine, University of Western Ontario, University of Maryland, Mc-
Gill University, University of Montreal, Notre Dame Hospital, Ackland UniServices, The
George Institute, Royal Perth Hospital, Sir Charles Gairdner Hospital, Royal Adlaide Hospital,
Royal Melbourne Hospital, Alfred Hospital, Royal North Shore Hospital, Westmead Hospital,
Royal Prince Alfred Hospital, Northwestern University, University of Ottawa, University of
Pittsburgh, Stanford University, University of California San Francisco, University of Southern
California, University of Virginia, University of Washington, University of Manitoba, Univer-
sity of Alabama Birmingham, Allegheny General Hospital, Brigham andWomen’s Hospital,
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Massachusetts General Hospital, University of Florida, Johns Hopkins University, University
of Michigan, and Washington University in St. Louis. Written consent was obtained from all
study participants.
Families were recruited to ensure that DNA could be obtained from at least two living af-
fected relatives and that the family would be informative for linkage analysis. Exclusion criteria
included (i) a fusiform-shaped unruptured IA of a major intracranial trunk artery; (ii) an IA
that is part of an arteriovenous malformation; (iii) a family or personal history of polycystic
kidney disease, Ehlers Danlos syndrome, Marfan’s syndrome, fibromuscular dysplasia, or
Moya-Moya disease; or (iv) failure to obtain informed consent from the patient or family
members. To identify unruptured IA, magnetic resonance angiography (MRA) was offered to
first degree relatives of affected family members who had a higher risk of IA as defined by: 1)
30 years of age or older and 2) either a 10 pack year history of smoking or an average blood
pressure of140 mmHg systolic or90 mmHg diastolic.
Only individuals having an IA based on an intra-arterial angiogram, operative report, autop-
sy, or size7 mm on non-invasive imaging (MRA) were considered “definite” cases (Table 1).
Two neurologists independently reviewed each record to determine if a subject met all inclusion
and exclusion criteria. In case of disagreement, a third neurologist reviewed the data.
Seven families of European American descent with the highest density of affected individuals
who also had DNA available were selected for WES [18] (Fig. 1). All affected individuals for
which sufficient DNA was available were selected for sequencing. Unaffected individuals were
selected only if there was an MRA conducted that confirmed the absence of an IA at 45 years or
older and if there was sufficient DNA available. One clinically unaffected individual in family E
was assumed to be an obligate carrier and was sequenced with her offspring to allow confirma-
tion of allele transmission. Within the seven families, 45 individuals were chosen for WES.
Whole Exome Sequencing
WES was performed at the Center for Inherited Disease Research (CIDR, Johns Hopkins Uni-
versity). Exonic sequences were captured using the Agilent SureSelect Human All Exon 50Mb
kit, and paired-end sequencing was performed on the Illumina HiSeq 2000 system, using Flow-
cell version 3 and TruSeq Cluster Kit version 3. All samples were genotyped using the Illumina
HumanOmniExpress-12v1_C platform for quality assurance. Two HapMap samples and two
study duplicates were used to ensure library preparation batch quality.
Whole Exome Sequencing Bioinformatics
Primary analysis was done using HiSeq Controls Software and Runtime Analysis Software. The
CIDRSeqSuite pipeline was used for secondary bioinformatics analysis, which consists mainly
Table 1. Disease phenotypes.
Classiﬁcation Deﬁnition
Deﬁnite Medical records document an intracranial aneurysm (IA) on angiogram, operative report, autopsy, or a non-invasive imaging report
(MRA, CTA) demonstrates an IA measuring 7mm or greater.
Probable Death certiﬁcate mentions probable IA without supporting documentation or autopsy. Death certiﬁcate mentions subarachnoid
hemorrhage (SAH) without mention of IA and a phone screen is consistent with ruptured IA (severe headache or altered level of
consciousness) rapidly leading to death. An MRA documents an IA that is less than 7 mm but greater than 3 mm.
Possible Non-invasive imaging report documents an aneurysm measuring between 2 and 3 mm or SAH was noted on death certiﬁcate, without
any supporting documentation, autopsy or recording of headache or altered level of consciousness on phone screen. Death certiﬁcate
lists ‘aneurysm’ without specifying cerebral location or accompanying SAH.
Not a case There is no supporting information for a possible IA.
doi:10.1371/journal.pone.0121104.t001
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of alignment using Burrows Wheeler Aligner (BWA version 0.5.9) [19] to the human genome
reference sequence (build hg19) and applying the Genome Analysis Toolkit (GATK version
1.0.4705) [20] to perform local realignment and base quality score recalibration. Duplicate
molecules were flagged and mate-pair information synchronized using Picard (version 1.52,
http://picard.sourceforge.net/). The GATK Unified Genotyper (GATK version 1.2–29) was
used for multi-sample variant calling. The dataset, consisting of called variants, subject pheno-
types, and pedigree information for the multiplex IA families can be requested directly from
the National Center for Biotechnology Information (NCBI) Database of Genotypes and Pheno-
types (dbGaP) (http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id =
phs000636.v1.p1) (accession phs000636). Mapped reads are available on the Sequence Read
Archive (http://www.ncbi.nlm.nih.gov/sra) (accession SRX329208-SRX329252).
GATK Variant Quality Score Recalibration (VQSR, GATK version 1.2–38) [21] created a
high-quality call set for SNVs by using an adaptive error model to estimate the likelihood of
true genotype calls based on aggregating information across multiple quality metrics. As rec-
ommended by GATK, HapMap 3.3 and the Illumina Omni 2.5M chip sites, available from the
GATK bundle 1.2, were used as training sets and the annotations of Quality by Depth,
Fig 1. Simplified pedigrees for the 7 whole exome sequencing families.Only sequenced individuals and those needed to preserve generational
structure are shown to protect the anonymity of the pedigree. IA = intracranial aneurysm. All affected individuals are definite IA unless noted as a probable IA,
possible IA, or aortic abdominal aneurysm (AAA). Criteria for defining definite, probable, and possible IA statuses are outlined in Table 1. All unaffected
individuals, with the exception of individual E-9, had an MRA performed that did not show evidence of an IA. Grey indicates an unknown phenotype. An ‘S’
above an individual denotes that the individual was selected for sequencing.
doi:10.1371/journal.pone.0121104.g001
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Haplotype Score, Mapping Quality Rank Sum, Read Position Rank Sum, Fisher Strand Bias
Test, and Mapping Quality were used as quality metrics for the recalibration. SNVs were fil-
tered until 99% of the overlapping HapMap 3.3 sites were retained after application of VQSR.
Insertion/deletions were removed if they had a quality by depth< 2.0, ReadPosRankSum
< -20.0 (Z-score fromWilcoxon rank sum test of alternative versus reference read position
bias), Fisher’s Strand Bias> 200.0 (phred-scaled p-value using Fisher’s exact test to detect
strand bias), and/or a homopolymer run> 5.
ANNOVAR [22] was used to annotate variants for location, predicted effect on the protein
across three gene databases (RefSeq, UCSC, and Ensembl), and corresponding gene and tran-
script length. Allele frequencies within European American populations in 1000 Genomes
(February 2012 release, http://www.1000genomes.org) [23] and the Exome Sequencing Project
(ESP) (ESP6500 release with insertion/deletions and chromosome X and Y calls, http://evs.gs.
washington.edu/EVS/) [24] were recorded using custom scripts. The scripts mapped variants
to 1000 Genomes and ESP based on chromosomal position and reference and alternate alleles
to determine allele frequencies. If a variant was not found in 1000 Genomes or ESP, the alter-
nate allele frequency was set to 0. If a variant was found in both 1000 Genomes and ESP, the
smaller alternate allele frequency was taken as the consensus frequency.
Variants were annotated for binned minor allele frequencies from 290 samples without a
known cardiovascular phenotype that were exome sequenced at CIDR using identical captur-
ing and sequencing technology, although SAMtools [25] was used for variant calling instead of
GATK Unified Genotyper. Variants that were monomorphic across all samples were
also flagged.
Variants were also annotated using custom scripts for Gene Ontology (GO) (http://www.
geneontology.org) [26] terms that were hypothesized to play a role in IA pathophysiology. GO
terms used included GO:0001944 (vasculature development), GO:0001570 (vasculogenesis),
GO:0003018 (vascular process in circulatory system), GO:0005581 (collagen), GO:0005604
(basement membrane), and GO:0051541 (elastin metabolic process).
Two programs were used to predict the pathogenicity of SNVs: SIFT [27] and PolyPhen-2
[28]. Scores of damaging for SIFT, or possibly or probably damaging for PolyPhen-2, were ac-
cepted as evidence for pathogenicity. Two additional programs were used to analyze the effect
of insertions and deletions: SIFT-INDEL [29] for those that cause a frameshift, and DDIG-in
for those that do not cause a frameshift [30]. Variants were also annotated for C-scores from
the Combined Annotation Dependent Depletion (CADD) webserver (http://cadd.gs.
washington.edu) [31]. C-scores of 10 or greater, corresponding to the 10% most deleterious
substitutions in the human genome according to CADD, were considered
damaging predictions.
Biological filtering retained loci if they: 1) were autosomal variants; 2) were predicted to be
nonsynonymous SNVs or insertion/deletions in an exonic and/or splicing region (within 2 bp
of a splicing junction, as annotated by ANNOVAR) based on RefSeq, UCSC, and Ensembl an-
notations; 3) had an allele frequency in European American populations<1% (1000 Genomes,
ESP); 4) had an allele frequency less than 1% in CIDR binned minor allele frequencies and
were not monomorphic across all samples; 5) were predicted most likely to be damaging by
CADD and by at least one other protein prediction program; and 6) segregated with all individ-
uals with a definite IA and obligate carriers in at least one family. All alignments for variants
passing these biological filters were visually inspected using the Integrated Genomics Viewer
[32] to confirm presence of a variant. Visual inspection for each variant included reviewing
read pair orientations, mappability, and soft-clipping; variants that were called nearby; overall
depth of sequencing and genomic features that might have inhibited coverage at that locus; and
repetitive sequence that might have influenced the position or variant allele called for the locus.
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In addition to the filters described above, insertion/deletions were also compared against a dif-
ferent dataset consisting of approximately 500 samples without a known cardiovascular pheno-
type. This comparison dataset used GATK Unified Genotyper (version 2.3–9) for variant
calling and the Agilent SureSelect Human All Exon 51Mb capture kit. If the allele designations
and/or positions did not match between the two datasets but were within 10 bp, manual review
of both the IA and comparison BAM files with IGV was done to reconcile differences in allele
designations and position assignments between the two datasets.
Loci were also annotated if they: A) segregated with all aneurysms (including probable and
possible IA and the one abdominal aortic aneurysm case in family G) and B) were not found in
any sequenced unaffected individuals, excluding assumed obligate carriers.
Linkage
The 7 families were included as part of a larger linkage study of 2,317 individuals from 394
families using the 6K Illumina array [9]. Multipoint parametric linkage analysis (autosomal
dominant inheritance, 1% disease allele frequency was performed using Merlin [33]. Only ge-
notypic data from family members with definite IA and obligate carriers were included in the
linkage analysis. WES variants were annotated for the highest LOD score obtained by linkage
markers within a 10Mb window centered on the sequencing variant. A maximum possible
LOD score for each family was calculated by simulating a hypothetical fully informative marker
using the aforementioned model parameters and the pedigrees for each family.
Tissue Collection for RNA Expression
Aneurysm biopsies from the aneurysm fundus distal to the clip were collected from patients
undergoing neurosurgical clipping of an IA at the Department of Neurology and Neurosurgery
in the University Medical Center Utrecht in the Netherlands. These patients were completely
independent of the families included for WES. Patients undergoing surgery because of intracta-
ble epilepsy were included as controls, and part of a superficial cortical artery in the resected
part of the brain was excised as control vessel tissue. Samples were collected from 44 aneurysm
biopsies (22 ruptured, 21 unruptured, 1 with unknown rupture status) and 16 control biopsies.
All samples were immediately snap frozen in liquid nitrogen less than 1 minute after excision
and stored at -80°C until further use.
RNA Isolation, Sample Preparation, and Sequencing
RNA isolation, sample preparation, and sequencing was conducted at the University Medical
Center Groningen in Groningen, the Netherlands. Each sample was homogenized with zirco-
nia/silica beads in the BeadBeater machine (BioSpec products, Inc.). After homogenization,
total RNA was extracted and purified using an RNeasy microkit (Qiagen, Valencia, CA, USA)
according to the manufacturer’s instructions. An initial quality check of the samples by capil-
lary electrophoresis and RNA quantification for each sample was performed using the LabChip
GX (PerkinElmer, Waltham, Massachusetts, USA). Samples with a minimum amount of 7 ng
non-degraded RNA were selected for subsequent sequencing analysis. Sequence libraries were
generated using the TruSeq RNA sample preparation kit from Illumina (San Diego, USA)
using the Sciclone NGS Liquid Handler (Perkin Elmer). To remove contamination of adapter-
duplexes, an extra purification of the libraries was performed with the automated agarose gel
separation system Labchip XT (Perkin Elmer). The obtained cDNA fragment libraries were se-
quenced on an Illumina HiSeq2000 using default parameters (single read 1x100bp) in pools of
10 or 11 samples. Processing of the raw data, including a demultiplexing step, was performed
using Casava software (Illumina) with standard settings.
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Differential Expression Analysis
Sequencing reads with quality score under Phred Score<30 were discarded. The quality fil-
tered trimmed fastQ files were then aligned to the human reference genome (hg19) using the
STAR aligner [34], allowing for 2 mismatches. SAMtools version 0.1.18 [25] was used to sort
the aligned reads. Gene level quantification was performed by HTSeq-0.5.4 [35] using parame-
ters—mode = union—stranded = no and Ensembl version 71 as the gene annotation database.
R version 3.1.0 was used for differential expression analysis. The counts per gene for each
sample obtained after alignment were used as input for the analysis. Low count genes (genes
with less than 1 read per million in n of the samples, where n is the size of the smallest group of
replicates, i.e. n = 16) were filtered out since there is little power to detect significant evidence
of differential expression in these genes [36].
The Bioconductor (version 2.14) packages edgeR (version 3.6.2) and limma (version 3.20.2)
were used for subsequent steps. To correct for technical influences, edgeR adjusts for varying
sequencing depths between samples and normalizes for the RNA composition of the sample. A
generalized linear model was used to test for differential expression between aneurysmal and
control tissue. Other factors included in the model were age and sex of patients, as well as rup-
ture status. Common and tagwise dispersion estimates were calculated with the Cox-Reid pro-
file adjusted likelihood method to be able to correct for the technical and biological variation
when fitting the multivariate negative binomial model. In estimating the tagwise dispersion,
the program default for degrees of freedom (df = 10) was used. A negative binomial generalized
log-linear model, using the tagwise dispersion estimates, was fitted to the read counts for each
gene, and a gene-wise statistical test was performed. Then, a likelihood ratio test was per-
formed. Benjamini Hochberg false discovery rates (FDR) for a transcriptome-wide experiment
were calculated to correct for multiple testing. All genes with an FDR adjusted p-value<0.05
were considered individual genes of interest.
Results
Sequencing Data Quality
The average study duplicate reproducibility of SNV and insertion/deletion calls were 99.13%
and 94.42%, respectively, and genotypes for non-reference calls per sample from the WES data
achieved an average 99.57% concordance with genotype calls from the Illumina HumanOm-
niExpress-12v1_C array. The average sensitivity to heterozygote calls on the array was 98.13%.
After application of GATK quality filters, 98,351 SNVs and 5,851 insertion/deletions were re-
tained. The transition-transversion ratio for exonic variants and percent of SNVs in dbSNP
137, both measures of the quality of the data, were 3.3 and 94.79% respectively.
Biological Filtering
The number of variants retained after each biological filter employed in the Methods is shown
in Tables 2–3 for SNVs and insertion/deletions, respectively. The list of SNVs and insertion/de-
letions satisfying biological filters 1–6 is shown in Table 4. The final candidate variants passing
biological filters 1–6 and manual inspection include 67 SNVs and 1 deletion. The sets of vari-
ants that A) segregate with all aneurysmal phenotypes and B) are not carried in unaffected in-
dividuals are included in Table 4 as subsets of the 68 final variants. The limitations of only
considering these sets of variants are described in the Discussion.
Of the 68 retained variants, five variants (found in the genes GSTCD, DUSP16, LMBR1L,
HAL, and TSC2) were found in definite IAs in two families; in all of these cases, the variant seg-
regated fully with definite IA in only one family. Two other variants (found in the genes
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COL17A1 and FOXM1) were the only variants of the 68 retained variants that were labeled
with vascular-related Gene Ontology annotations (i.e. GO:0005604 basement membrane and
GO:0005581 collagen; and GO:0001570 vasculature development and GO:0001570 vasculo-
genesis; respectively).
Linkage
The distribution of genome-wide LOD scores for each family is depicted in Figs. S1, S2, S3, S4,
S5, S6, and S7, with the WES variants satisfying biological filters 1–6 superimposed. The maxi-
mum possible LOD score for each family given the model parameters and the specific pedigree
structure is also reportedThe highest LOD score obtained by linkage markers within a 10Mb
window centered on each sequencing variant is recorded in Table 4. Of the 68 WES variants
satisfying biological filters 1–6 and manual inspection, 23 variants had a LOD score for a link-
age marker within 10Mb of the sequencing variant that fell within 0.01 of the highest possible
LOD score for that family.
The 23 variants within a possible linkage peak were distributed among all families except
family F, where the highest LOD score for a linkage marker within 10Mb of a filtered
Table 2. Single nucleotide variant filtering pipeline.
Family A B C D E F G All
All variants found in at least one deﬁnite IA 46168 41978 44689 44515 49142 39495 37809 98351
(1) Autosomal variants 45390 41280 43994 43701 48376 38925 37251 96552
(2) Variants predicted to be functional 12261 11158 11849 11841 13203 10578 10025 29194
(3) Rare variants 1020 889 953 1298 1356 843 823 7845
(4) Variants not found or of low frequency in the internal allele frequency database 793 725 740 1028 1049 676 658 6428
(5) Variants predicted damaging 393 345 369 442 470 297 306 3008
(6) Variants segregating with all deﬁnite IA in at least one family 13 11 2 10 4 8 24 67
Variants passing visual inspection 13 11 2 10 4 8 24 67
A. Variants segregating with all IA (deﬁnite, probable, possible) or AAA in at least
one family
13 9 2 8 3 8 7 46
B. Variants not found in unaffected individuals 5 2 1 7 3 1 0 19
Numbers in parentheses refer to ﬁltering steps described in the Methods. IA = intracranial aneurysm
doi:10.1371/journal.pone.0121104.t002
Table 3. Insertion deletion filtering pipeline.
Family A B C D E F G All
All variants found in at least one deﬁnite IA 3316 2736 3226 3166 3396 2987 2966 5851
(1) Autosomal variants 3264 2705 3178 3102 3345 2940 2921 5737
(2) Variants predicted to be functional 538 457 560 541 581 511 465 1126
(3) Rare variants 284 221 299 277 299 266 260 589
(4) Variants not found or of low frequency in the internal allele frequency database 178 159 188 171 192 165 157 453
(5) Variants predicted damaging 60 59 65 50 59 55 42 194
(6) Variants segregating with all deﬁnite IA in at least one family 24 22 23 19 23 24 19 26
Variants passing visual inspection and manual review with internal database calls 0 0 0 0 0 0 1 1
A. Variants segregating with all IA (deﬁnite, probable, possible) or AAA in at least one family 0 0 0 0 0 0 0 0
B. Variants not found in unaffected individuals 0 0 0 0 0 0 0 0
Numbers in parentheses refer to ﬁltering steps described in the Methods. IA = intracranial aneurysm
doi:10.1371/journal.pone.0121104.t003
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sequencing variant was 0.83 but the highest possible LOD score for the family was 1.12. Family
B had the most retained variants within possible linkage peaks (n = 9); followed by family D
(n = 4); families A, E, and G (n = 3); and family C (n = 1). Of the 23 variants, only 8 also met
the optional prioritization criteria of segregating with all aneurysmal phenotypes and not being
carried by an unaffected individual (KLF11 variant in family A, variants in ABCC3 and TANC2
in family B, variants in ALMS1 and ARHGEF17 in family D, and variants in SMEK2,HTRA2,
and NDST1 in family E).
While none of the 68 variants coincided with well-established GWAS association signals, 6
of the variants were found within IA linkage peaks identified in previously published family
studies, independent of the families in this report. Four variants (found in the genes C1orf38,
PTAFR, ZNF362, andMAP7D1) fell within the linkage peak 1p34.3–36.13 [7, 8], while 2 vari-
ants (found in the genes ROBO3 and FOXRED1) were located in the linkage peak 11q24–25
[10–12]. None of these 6 genes were suggested as candidate genes by the authors of the pub-
lished linkage studies. The linkage regions each cover hundreds of genes, as they span approxi-
mately 24 and 14 Mb respectively.
RNA Expression
Expression data was obtained in 51 of the 68 candidate genes in an independent set of IA cases
and controls. Log fold changes and FDR-adjusted p-values for each gene is displayed in
Table 4. Only 1 gene (TMEM132B) of the 51 genes showed differential expression (overex-
pressed with log fold change = 2.63, FDR-adjusted p-value = 0.023).
Discussion
TMEM132B
Exome sequencing presents an opportunity to explore the contribution of rare variation to
complex disorders like IA. We have used this approach to identify 68 rare variants in 68 genes
that segregate within 7 densely affected families. Of the 51 genes that were expressed in IA tis-
sue, one gene (TMEM132B) was found to be significantly overexpressed in IA tissue in com-
parison to control vascular tissue.
TMEM132B, or transmembrane protein 132B, is a relatively uncharacterized protein of un-
known function. The variant segregating in the family is rare (0.024% frequency in European
American samples in the Exome Sequencing Project and not found in 1000 Genomes) and pre-
dicted damaging by SIFT, PolyPhen-2, and CADD due to a change from the polar amino acid
serine to the nonpolar amino acid leucine at a highly conserved position. Each of the individu-
als with a definite IA in family D was heterozygous for the variant. Mutations inherited in a
dominant manner often lead to a disease phenotype through a gain of function mechanism,
which would be supported by the overexpression of TMEM132B in IA tissue as compared to
control vessels. It is also possible, however, that dominantly-inherited mutations exert their ef-
fect via haploinsufficiency or dominant negative mechanisms. Further studies are required to
confirm the role of TMEM132B in IA and through what mechanism the variant identified in
this study may act.
The TMEM132B variant was not inherited by individual 11 in family D. Individual 11 was
diagnosed as a possible IA due to the presence of a small aneurysm identified through non-in-
vasive imaging (i.e. 1–2mm, verified by 3 independent neurologists). This is in contrast to the
definite IAs clearly identified in this individual’s sibling and cousins; thus, individual 11 is
most likely actually unaffected.
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Prioritization of Variants within Families
Expression information was only available for 51 of the 68 candidate genes; thus, RNA expres-
sion cannot confirm or rule out the role of the remaining 17 genes in IA pathophysiology. Ad-
ditionally, a subset of the other 50 variants with expression data may also contribute to IA in
ways not captured by the RNA expression experiment and should be explored. In order to fur-
ther study the cause of IA in each of the remaining families, candidate variants in each family
must be prioritized.
In families C and E, segregation analysis reduced the number of prioritized variants to only 2
and 4 variants, respectively. For family C, the two variants have a CADD score>20. The variant
in SEC16B is not found within a potential linkage peak; however, in support of its potential sig-
nificance in disease susceptibility, it is not carried by any tested unaffected family member. The
variant in C11orf65, on the other hand, is found within a potential linkage peak but is also inher-
ited by an unaffected family member. For family E, three variants segregate in the family (and a
fourth variant in GSTCD is found in only one individual in family E but segregates fully in fami-
ly G). The three variants that segregate in the family (in genes SMEK2,HTRA2, andNDST1) all
are found within potential linkage peaks. Data are not available from any unaffected family
members. Therefore, further prioritization among these three variants could incorporate CADD
scores, which range from 11.98 for theHTRA2 variant to 23.9 for the SMEK2 variant.
Considerations for Pedigree and Phenotypic Data
It is possible that genetic heterogeneity, phenocopies, or gene-environment interactions could
explain one or more IAs in the families chosen for this study. In this case, the criterion requir-
ing all affected individuals to share a variant would miss important disease-contributing vari-
ants. Similar family-based sequencing studies in the future could relax this segregation
criterion with the recognition that a much larger number of variants will be retained. Family-
based aggregative association tests that incorporate different penetrance models could also be
employed with a larger number of samples.
The availability and quality of clinical data is also critical to consider in complex disease
WES studies. In this study, several families also had individuals with probable and possible IAs
(see Table 1 for phenotype definitions), and one family also had an occurrence of an abdominal
aortic aneurysm (Fig. 1). Given the high density of definite IAs in these families, it is likely that
some or all of the probable and possible IAs have disease due to the same disease-contributing
variant. Additionally, given the possible genetic link between different forms of aneurysms
[37], the abdominal aortic aneurysm may also share the same genetic etiology within that fami-
ly. We thus flagged variants that segregated fully among all individuals with an aneurysm (defi-
nite, probable, or possible IA, or an abdominal aortic aneurysm) (Tables 2–3). This represents
a possible method for prioritizing variants for further study, with the caveat that including
non-definite IAs increases the likelihood of genetic heterogeneity, phenocopies, and gene-
environment interactions.
Another approach to prioritize variants for further study is to utilize genotypic data from
unaffected individuals. The ability of this approach to rapidly narrow down the number of vari-
ants under consideration is readily apparent from this study (Tables 2–3), but there are major
concerns about inflating false negative rates by using unaffected individuals. Given the tradi-
tionally late age of onset for intracranial aneurysms, only individuals who had an MRA con-
firming the absence of IA at age 45 or older were sequenced as unaffected samples. Despite
these precautions, the unaffected individuals in this study were still relatively close in age to the
age at diagnosis of their relatives who had an IA, and it is possible that the unaffected individu-
als will actually develop an IA later in life due to a genetic predisposition.
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The difficulty in defining an unaffected also surfaces when considering the putative obligate
carriers in these families. In Family A, individual A-7 also had an MRA done at age 64 that ex-
cluded the presence of an IA, yet we would posit that this individual likely passed a causative
genetic variant to her daughter (A-10), whose IA is more likely to have a genetic basis due to
her young age of onset. Without the daughter’s data, individual A-7 would have likely been
chosen as an unaffected individual for sequencing, especially given that she had major environ-
mental risk factors (a history of smoking and hypertension). In Family E, the sequenced indi-
vidual E-9 is also an obligate carrier under our model. Unlike individual A-7, an MRA could
not be obtained on individual E-9, and she did not have a history of smoking or hypertension.
Since all affected individuals in family E had at least one environmental risk factor and individ-
ual E-9 did not, it is possible that the causative genetic variant in family E requires an additional
environmental insult to lead to IA development. The importance of strong environmental risk
factors such as smoking to the development of aneurysms, even in the context of rare causal ge-
netic variants, cannot be underestimated. Alternative methods of prioritization of variants that
incorporate this possibility should be explored. Thus, unaffected status in this study was used
as a mechanism for possible prioritization but not for automatic exclusion of variants. The abil-
ity to use unaffected individuals will vary in studies of different diseases and will likely be more
fruitful in those diseases that appear to have a smaller environmental/lifestyle contribution.
For future family-based sequencing studies in complex disease, it may not be feasible to se-
quence as many individuals per pedigree as was done for this study. Thus, it is critical to care-
fully select samples based on the quality of phenotyping and the pedigree structure. Recently
developed tools offer statistical methods to select related subjects for sequencing based on ge-
netic distance [38], samples that span multiple generations (Exome Picks, http://genome.sph.
umich.edu/wiki/ExomePicks), and a combination of both of these methods [39]. As evident
from Tables 2–3, selecting families with more closely related individuals, such as families with
full siblings as in Families F and G, will yield a smaller number of initially called variants across
the family. Yet, the power to narrow down the number of variants segregating with disease is
diminished in such families due to the naturally larger percentage of alleles shared, as com-
pared to families with individuals in multiple generations such as in Family C. Thus, where
possible, selection of more distantly related family members for sequencing studies will have
greater power to generate a narrowed list of prioritized variants.
For some families, it may be possible to combine linkage and sequencing data to find causa-
tive variants. The families sequenced in this study were included as a part of a larger linkage
study reported previously [9]. The same model parameters used for WES variant filtering was
applied for multipoint linkage analysis. Since any given marker may have been uninformative
for a family, a maximum LOD score was reported within a 10Mb window of the sequence vari-
ant’s chromosomal position. Although only modest evidence of linkage was obtained, several
sequencing variants lay within the linkage regions in these families (S1, S2, S3, S4, S5, S6, and
S7 Figs.). Many variants, however, did not overlap with any evidence of linkage, suggesting that
these families were either not fully informative for robust linkage analysis near these loci, or
the sequencing variants identified are not causative genetic variants in these families.
Considerations for Exonic Variation
In recent years, WES has emerged as a practical method for systemically exploring rare coding
variation. Since the majority of known genetic causes of Mendelian disorders affect protein
coding regions [40], the exome is a logical starting place to identify potentially causative vari-
ants in diseases that exhibit Mendelian inheritance. The densely-affected families sequenced in
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this study appear to display autosomal dominant inheritance; therefore, we hypothesized that
coding variants may explain most or even all of these cases.
Due to imperfect capture and alignment, WES generates some off-target, non-exonic variant
calls. While it is possible that important variation exists in these off-target regions, a higher per-
centage of calls in these regions are of poorer quality. Thus, only those variants within exonic or
splicing regions were retained in this experiment. Since different databases contain different
numbers of and boundaries for genes and exons [41], a consensus prediction of gene and exon
boundaries was made to determine those variants that fell within exonic or splicing regions. In
order to minimize the type I error rate by using functional predictions of the highest confidence,
the intersection of functional predictions from three different databases (RefSeq, UCSC, and
Ensembl) was used for this study. Thus, variants were only retained if they were predicted by all
three databases to be within exonic or splicing regions. Other WES studies may choose to gener-
ate a larger set of variants by prioritizing all variants in the union rather than the intersection of
functional predictions frommultiple databases; however, appropriate methods for validating
variants with functional predictions that differ by database should be employed.
It is possible that non-coding variants and/or epistatic interactions are important in IA de-
velopment in these families and in other complex diseases, in which case alternate study de-
signs should be utilized. At the time of this study, whole genome sequencing could have only
been employed at the expense of sequencing fewer individuals, and annotations and bioinfor-
matics tools available for non-coding sequence were less robust. Given that whole genome se-
quencing generates about 3 million SNVs per genome [42], annotations and bioinformatics
tools are even more critical for practical prioritization of candidate variants. In the future, tech-
niques like whole genome sequencing, as well as targeted resequencing, transcriptome sequenc-
ing, and other high throughput study designs, can be applied to fully catalogue the role of
genetic variation in IA development.
Considerations for Allele Frequency
The average individual has around 15,000 exonic single nucleotide variants (SNVs) differing
from the reference human genome sequence [24]. In order to narrow down the number of vari-
ants identified by a WES study, initial studies [43, 44] focused on rare diseases and limited
analysis to novel variants. This strategy is too restrictive for more common diseases such as IA.
In the particular subset of families used for this study, there is a uniquely high incidence of IA,
which enriches for the possibility of identifying rare, highly penetrant variants of larger effect
sizes. Rare variants and less common variants are typically defined as less than 1% and 1–5%
minor allele frequency, respectively [45, 46]. Given the rarity of families that are as densely af-
fected as the ones in this study, a 1% minor allele frequency threshold was set. It is possible,
however, that a variant of higher minor allele frequency causes IA in one or more of these fami-
lies. Future studies with a much larger sample size could employ aggregative association tests
[47] with relaxation of the allele frequency threshold.
In this study, allele frequencies specifically from European American populations were
available from public databases. Given that rare variants can be population-specific [48], the se-
lection of appropriate allele frequency databases is critical. In lieu of publicly available allele fre-
quencies, future studies may consider sequencing a large number of internal controls and
possibly requesting commonly available controls to sequence as well. While not feasible for the
current study, such a design would help control for platform- and pipeline-specific artifacts in
sequencing while ensuring phenotyping quality for controls.
While it is standard for WES studies to utilize public databases to filter variants, it is also
valuable to use internal frequency databases that are specific to the sequencing and variant
Lessons fromWhole Exome Sequencing in Familial Intracranial Aneurysm
PLOSONE | DOI:10.1371/journal.pone.0121104 March 24, 2015 18 / 25
calling pipeline. Because variant calling can be lab-specific due to the technology used, in this
study variants were annotated for binned minor allele frequencies from 290 unrelated samples
without a known cardiovascular phenotype that were exome sequenced at CIDR. Thus variants
that would have otherwise been considered rare or novel when compared against public data-
bases, but that were actually a recurring artifact of the sequencing, were captured as having a
high CIDR binned minor allele frequency. Given that the bioinformatics pipeline used in this
study differed slightly from that of the internal database, the internal database filter may have
missed some artifacts specific to the variant calling method. Variants that were monomorphic
(i.e. all heterozygous or homozygous for the alternate allele) across all samples were also re-
moved since it is highly unlikely that the identical rare disease-causing allele would be shared
by both affected and unaffected individuals in multiple families.
Insertion/deletion allele frequencies in both internal and external databases are inherently
less accurate than frequencies for SNVs, due to the increased difficulty and variation in calling
structural variants. Also, differences in how position coordinates are assigned as well as refer-
ence and alternate allele designations further makes comparison challenging. The 26 insertion/
deletions that passed biological filters 1–6 (described in the Methods) in all cases except for one
were shared in almost all or all of the 7 families sequenced in this study. Just as variants that
were monomorphic across all datasets were removed as probable sequencing or pipeline arti-
facts, it is very unlikely that any given rare disease-causing insertion/deletions would also be
shared across all or almost all families in a complex disease. It is possible that multiple families
may carry different disease-causing insertion/deletions in the same gene, but this pattern was
not seen. Thus, a second internal frequency comparison set of 500 samples that had a more
similar bioinformatics pipeline to the IA samples sequenced in this study (i.e. use of GATK
Unified Genotyper for variant calling) was used for manual review in combination with IGV
visual inspection for the 26 insertion/deletions remaining after application of biological filters.
Manual review as described in the Methods excluded all but one of the 26 insertion/deletions,
demonstrating that manual inspection and use of an internal dataset generated by a similar bio-
informatics pipeline are critical for reviewing insertion/deletions in sequencing experiments.
Future studies may also consider utilizing newer local re-assembly-based methods for variant
calling, such as FreeBayes [49] or GATK’s HaplotypeCaller, which may improve the accuracy
of insertion/deletion calls.
Consideration for Functional Predictions of Exonic Variation
More severe amino acid substitutions are more likely to present clinically [40], so most WES
studies to date have focused on non-synonymous SNVs and insertion/deletions. In this study,
we also opted to focus on these variants, as predicted by the intersection of the three gene data-
bases (RefSeq, UCSC, and Ensembl). Future studies focused on exonic variation could also
study the effect of synonymous variation, which has been shown to also play an important role
in human disease [50]. At the time of this study, fewer validated tools existed to examine the
role of synonymous variation in sequencing data.
In this study, several programs were used to measure the level of conservation of a locus and
the predicted pathogenicity of a variant. The programs have varying degrees of sensitivity and
specificity for different kinds of variants, particularly due to the use of different but not
completely independent data sources when generating predictions [51]. The bioinformatics
community is working to develop tools that will be able to better integrate information to pro-
vide a more informed pathogenicity prediction. One such tool, the CADD program [31], was
recently introduced but has not been applied to a large number of datasets. Since there are few
published studies implementing CADD, we have conservatively removed only variants with a
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C-score<10, thus retaining variants that are predicted by CADD to be among the 10% most
deleterious substitutions in the human genome.
Considerations for Biological Processes and Pathways
The filtering schema did not employ any assumptions about biological processes or pathways.
Variants were annotated for GO terms chosen for possible relation to IA formation; however,
only two variants in the final candidate variant list (variants found in the genes COL17A1 and
FOXM1) had one or more of these GO annotations. While using GO annotations as a filter is a
powerful method for narrowing a list of variants, such an approach would depend on the com-
prehensiveness of GO annotations, as well as the reliability of investigator-chosen GO terms.
To avoid subjectivity in selecting biological processes or pathways, future studies with larger
sample sizes should consider employing formal gene set enrichment analysis, which eliminates
the need to choose pathways a priori. Even for smaller datasets, use of GO annotations may
help determine which gene variants to pursue first in additional experiments to explore possi-
bly causal associations between the variant and disease of interest.
Summary and Future Directions
This is one of the few studies published to date that apply WES in a cohort of well-character-
ized families densely affected with a common complex disease without an a priori focus on a
particular pathway or genomic region. We have laid out many considerations for future WES
studies in complex disease, including the use of pedigree and phenotypic data, defining gene
and exon boundaries, sources for allele frequency estimates, proper interpretation of in silico
functional predictions, the role of environmental factors in the determination of potentially
causal rare variants, and the possible utility of combining pathway information with
sequencing data.
In this study, 68 rare exonic variants in 68 genes were identified. Of these genes, one gene
(TMEM132B) was significantly differentially expressed in IA versus control tissue. Further
studies are needed to confirm and explore the TMEM132B variant, as well as the possible con-
tribution of the other 67 variants. Replication and/or meta-analysis with similar sequencing
studies using larger sample sizes could be used to gather further evidence for specific genes on
this list. Additionally, a subset of these variants, which can be prioritized through any of the
methods discussed in this study, could be explored through functional studies in models where
vascular phenotypes can be easily observed, such as zebrafish. Targeted gene editing, such as
through the CRISPR-Cas system, could help test whether a given variant disrupts the normal
functioning of the relevant gene and whether such a disruption leads to a phenotype of interest.
Ultimately, such a model should also enable investigation of whether the disrupted phenotype
can be rescued by reintroduction of the wild type allele or interference with the variant allele.
For comprehensive exploration of the variants identified in this study, multiple methods of ex-
perimental validation may be necessary. This study represents a necessary first step in the eval-
uation of role of rare variants in a common complex disease. Further evaluation in other
familial and sporadic samples, as well as multi-ethnic samples, will be essential.
Supporting Information
S1 Fig. Summary of genome-wide multipoint linkage analysis for Family A. Details of the
disease-specific modeling are described in the Methods. Positions of candidate single nucleo-
tide variants and insertion/deletions identified in the whole exome sequencing data are denoted
by diamonds and crosses, respectively.
(TIF)
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S2 Fig. Summary of genome-wide multipoint linkage analysis for Family B. Details of the
disease-specific modeling are described in the Methods. Positions of candidate single nucleo-
tide variants and insertion/deletions identified in the whole exome sequencing data are denoted
by diamonds and crosses, respectively.
(TIF)
S3 Fig. Summary of genome-wide multipoint linkage analysis for Family C. Details of the
disease-specific modeling are described in the Methods. Positions of candidate single nucleo-
tide variants and insertion/deletions identified in the whole exome sequencing data are denoted
by diamonds and crosses, respectively.
(TIF)
S4 Fig. Summary of genome-wide multipoint linkage analysis for Family D. Details of the
disease-specific modeling are described in the Methods. Positions of candidate single nucleo-
tide variants and insertion/deletions identified in the whole exome sequencing data are denoted
by diamonds and crosses, respectively.
(TIF)
S5 Fig. Summary of genome-wide multipoint linkage analysis for Family E. Details of the
disease-specific modeling are described in the Methods. Positions of candidate single nucleo-
tide variants and insertion/deletions identified in the whole exome sequencing data are denoted
by diamonds and crosses, respectively.
(TIF)
S6 Fig. Summary of genome-wide multipoint linkage analysis for Family F. Details of the
disease-specific modeling are described in the Methods. Positions of candidate single nucleo-
tide variants and insertion/deletions identified in the whole exome sequencing data are denoted
by diamonds and crosses, respectively.
(TIF)
S7 Fig. Summary of genome-wide multipoint linkage analysis for Family G. Details of the
disease-specific modeling are described in the Methods. Positions of candidate single nucleo-
tide variants and insertion/deletions identified in the whole exome sequencing data are denoted
by diamonds and crosses, respectively.
(TIF)
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